Angle PLC WEBINAR:USING PARSORTIX TO TEST DRUGS ON LIVE CTCS
January 16 2018 - 02:00AM
RNS Non-Regulatory
TIDMAGL
Angle PLC
16 January 2018
For immediate release 16 January 2018
ANGLE plc ("the Company")
WEBINAR: USING THE PARSORTIX(TM) SYSTEM TO IDENTIFY DRUGS THAT
MAY ARREST CANCER METASTASIS
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company, announces that Professor Stuart Martin from the University
of Maryland School of Medicine, USA, will be presenting a webinar
describing his breakthrough work using the Parsortix(TM) system to
test drugs on live circulating tumor cells (CTCs) as was described
in the Company's announcement on 9 October 2017.
The webinar is intended for cancer researchers but is also open
to investors and other interested parties. The details are as
follows:
"Microfluidic Cell Tethering Enables Rapid Analysis of Drug
Responses in Live Patient CTCs"
Wednesday 17 January 2018 from 5pm to 5:50pm UK time.
Participants need to register in advance using the following
link
https://register.gotowebinar.com/register/5646294960950153218
Over 90% of deaths from cancer arise from the process of
metastasis where the cancer spreads throughout the body via CTCs in
the blood causing secondary cancers. If drugs can be identified for
the patient that disable their CTCs then the metastatic spread of
the disease might be arrested or reduced.
For further information ANGLE:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
finnCap Ltd (NOMAD and Joint
Broker)
Corporate Finance - Adrian
Hargrave, Simon Hicks, Kate
Bannatyne
Corporate Broking - Alice Lane,
Nikita Jain +44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes +44 (0) 203 705 9318
Nigel Birks +44 (0) 203 705 9316
FTI Consulting
Simon Conway, Mo Noonan, Stephanie
Cuthbert +44 (0) 203 727 1000
Kimberly Ha (US) +1 212 850 5612
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world-leading liquid biopsy company commercialising a
disruptive platform technology that can capture cells circulating
in blood, such as cancer cells, even when they are as rare in
number as one cell in one billion blood cells, and harvest the
cells for analysis.
ANGLE's cell separation technology is called the Parsortix(TM)
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix(TM) is the subject
of granted patents in Europe, the United States, Canada, India,
China, Japan and Australia and three extensive families of patents
are being progressed worldwide. The system is based on a
microfluidic device that captures live cells based on a combination
of their size and compressibility. Parsortix(TM) has a CE Mark for
Europe and FDA authorisation is in process for the United
States.
ANGLE has established formal collaborations with world-class
cancer centres. These Key Opinion Leaders are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. Details are available here
http://www.angleplc.com/the-company/collaborators/
The analysis of the cells that can be harvested from patient
blood with ANGLE's Parsortix(TM) system has the potential to help
deliver personalised cancer care offering profound improvements in
clinical and health economic outcomes in the treatment and
diagnosis of various forms of cancer.
The global increase in cancer to a 1 in 3 lifetime incidence is
set to drive a multi-billion dollar clinical market. The
Parsortix(TM) system is designed to be compatible with existing
major medtech analytical platforms and to act as a companion
diagnostic for major pharma in helping to identify patients that
will benefit from a particular drug and then monitoring the drug's
effectiveness.
As well as cancer, the Parsortix(TM) technology has the
potential for deployment with several other important cell types in
the future.
ANGLE stock trades on the AIM market of the London Stock
Exchange under the ticker symbol AGL and in New York on the OTC-QX
under the ticker symbol ANPCY. For further information please
visit: www.angleplc.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEAPFSFFEPEFF
(END) Dow Jones Newswires
January 16, 2018 02:00 ET (07:00 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Feb 2024 to Mar 2024
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2023 to Mar 2024